BostonGene and Prisma Health Announce Collaboration Aimed at Predicting Efficacy of Immunotherapy in Rare Cancers

BostonGene multi-omics analytics to uncover unique molecular characteristics to personalize treatment plans for patients with rare tumors

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-based molecular and immune profiling solutions provider, today announces a collaboration with Prisma Health aimed at advancing the understanding of rare tumors by characterizing the tumor microenvironment (TME), mutational landscape and host immune profiles of patients treated with immune checkpoint inhibitors.

In collaboration with Prisma Health’s Rare Tumor Center, BostonGene will analyze tissue and peripheral blood from rare cancer solid-tumor patients to understand the molecular underpinnings of immune-activating drugs commonly used to enhance a person's innate mechanisms to fight cancer. BostonGene will perform detailed analyses of primary tumors and immunoprofiling of matched peripheral blood collected during this cohort of the trial, which is currently enrolling patients.

Prisma Health, the largest healthcare system in South Carolina, established its Rare Tumor Center in 2014 with a focus on improved outcomes for patients with rare cancers. By adding AI-powered molecular profiling to its long-running prospective clinical trial on checkpoint inhibitors, Prisma Health’s physician researchers hope to gain a substantially deeper understanding, not just of cancer, but of cancer’s interaction with the surrounding tissue and normal supportive cells. The center is part of the Prisma Health Cancer Institute, which actively participates in more than 300 clinical trials annually.

“BostonGene’s innovative solutions will provide a substantially deeper understanding of the molecular profiles of rare tumor patients, which could help us better determine what therapies work for which patients,” said Jeffrey Edenfield, MD, medical director for Prisma Health’s Institute for Translational Oncology Research and founder of its Rare Tumor Center. “We are excited about the opportunity to identify potential molecular markers of treatment response and, in turn, improve patient outcomes.”

“We’re honored to collaborate with Prisma Health for this prospective clinical trial,” said Nathan Fowler, MD, chief medical officer at BostonGene. “We are confident that our next-generation multi-omics analytics will uncover unique molecular characteristics that can be utilized to personalize treatment plans for patients with rare tumors.”

BostonGene’s computational platform integrates genomic, transcriptomic and immunoprofiling data to assess the TME and corresponding host immune status to characterize somatic alterations, gene expression, fusions, tumor heterogeneity, the TME and immunoprofiles.

Visit ClinicalTrials.gov for more information on the protocol, A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Rare Solid Tumors.

About BostonGene Corporation
BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

About Prisma Health
Prisma Health is a private nonprofit health company and the largest healthcare organization in South Carolina. The company has 29,500 team members, 18 acute and specialty hospitals, 2,947 beds, 300 outpatient sites, and more than 5,100 employed and independent clinicians across its clinically integrated inVio Health Network. Along with this innovative network, Prisma Health serves almost 1.5 million unique patients annually in its 21-county market area that covers 50% of South Carolina. Prisma Health’s goal is to improve the health of all South Carolinians by enhancing clinical quality, the patient experience and access to affordable care, as well as conducting clinical research and training the next generation of medical professionals. Learn more at PrismaHealth.org.